Claims for Patent: 5,110,493

Summary for Patent: 5,110,493

Title:	Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
Abstract:	Stable, clear, antimicrobially effective, ophthalmic formulations include an ophthalmologically effective amount of a drug, especially a --COOH group-containing drug or a NSAID, and a preservative system formed of a quaternary ammonium preservative and a nonionic surfactant, all in an aqueous vehicle. These formulations are useful for treating diseases that are either caused by, associated with or accompanied by inflammatory processes, including, among others, glaucoma, cystoid macular edema, uveitis, diabetic retinopathy and conjunctivitis, or any trauma caused by eye surgery or eye injury.
Inventor(s):	Cherng-Chyi; Roger F. (Los Altos, CA), Lidgate; Deborah M. (Los Altos, CA)
Assignee:	Syntex (U.S.A.) Inc. (Palo Alto, CA)
Application Number:	07/624,027
Patent Claims:	1. An ophthalmologically acceptable non-steroidal anti-inflammatory drug formulation, comprising: an ophthalmologically acceptable non-steroidal anti-inflammatory carboxyl group-containing drug in an effective amount for ophthalmic treatment between 0.001% and 10.0% wt/vol; a quaternary ammonium preservative in an antimicrobially effective amount between 0.001% and 1.0% wt/vol; an ethoxylated alkyl phenol that conforms generally to the formula: C.sub.8 H.sub.17 C.sub.6 H.sub.4 (OCH.sub.2 CH.sub.2).sub.n OH where n has an average value of 40 in a stabilizing amount between 0.001% and 1.0% wt/vol; and an aqueous vehicle q.s. to 100%. 2. The ophthalmologically acceptable non-steroidal anti-inflammatory drug formulation of claim 1 wherein said quaternary ammonium preservative is benzalkonium chloride. 3. The ophthalmologically acceptable non-steroidal anti-inflammatory drug formulation of claim 2 wherein said ophthalmologically acceptable non-steroidal anti-inflammatory carboxyl group-containing drug is selected from the group selected from ketorolac, indomethacin, flurbiprofen, and suprofen. 4. The ophthalmologically acceptable non-steroidal anti-inflammatory drug formulation of claim 3 wherein said ophthalmologically acceptable non-steroidal anti-inflammatory carboxyl group-containing drug is ketorolac tromethamine. 5. The ophthalmologically acceptable non-steroidal anti-inflammatory drug formulation of claim 1, further comprising: a chelating agent in an amount between 0.01% and 1.0% wt/vol; a tonicifier q.s. to achieve isotonicity with lacrimal fluid; and 1N NaOH or 1N HCl q.s. to adjust pH to 7.4.+-.0.4. 6. The ophthalmologically acceptable non-steroidal anti-inflammatory drug formulation of claim 1 comprising: 7. The ophthalmologically acceptable non-steroidal anti-inflammatory drug formulation of claim 6 comprising: 8. A method of treating an ophthalmic disease caused by, associated with, or accompanied by inflammatory processes, comprising administering to a mammal suffering therefrom a formulation comprising: an ophthalmologically acceptable non-steroidal anti-inflammatory carboxyl group-containing drug in an effective amount for ophthalmic treatment between 0.001% and 10.0% wt/vol; a quaternary ammonium preservative in an antimicrobially effective amount between 0.001% and 1.0% wt/vol; an ethoxylated alkyl phenol that conforms generally to the formula: C.sub.8 H.sub.17 C.sub.6 H.sub.4 (OCH.sub.2 CH.sub.2).sub.n OH where n has an average value of 40 in a stabilizing amount between 0.001% and 1.0% wt/vol; and an aqueous vehicle q.s. to 100%. 9. The method of claim 8, wherein said quaternary ammonium preservative is benzalkonium chloride. 10. The method of claim 9 wherein said ophthalmologically acceptable non-steroidal anti-inflammatory carboxyl group-containing drug is selected from the group selected from ketorolac, indomethacin, flurbiprofen, and suprofen. 11. The method of claim 10 wherein said ophthalmologically acceptable non-steroidal anti-inflammatory carboxyl group-containing drug is ketorolac tromethamine. 12. The method of claim 8 wherein the formulation further comprises: a chelating agent in an amount between 0.01% and 1.0% wt/vol; a tonicifier q.s. to achieve isotonicity with lacrimal fluid; and 1N NaOH or 1N HCl q.s. to adjust pH to 7.4.+-.0.4. 13. The method of claim 8 wherein the formulation comprises: 14. The method of claim 13 wherein the formulation comprises: 15. An antimicrobially effective preservative system for an ophthalmologically acceptable non-steroidal anti-inflammatory carboxyl group-containing drug formulation, comprising: a quaternary ammonium preservative in an antimicrobially effective amount between 0.001% and 1.0% wt/vol of the formulation; and an ethoxylated alkyl phenol that conforms generally to the formula: C.sub.8 H.sub.17 C.sub.6 H.sub.4 (OCH.sub.2 CH.sub.2).sub.n OH where n has an average value of 40 in a stabilizing amount between 0.001% and 1.0% wt/vol of the formulation. 16. The preservative system of claim 15 wherein said preservative is benzalkonium chloride.